-
1
-
-
0037295403
-
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
-
Liu, B.L., Robinson, M., Han, Z.Q. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003, 10(4): 292-303.
-
(2003)
Gene Ther
, vol.10
, Issue.4
, pp. 292-303
-
-
Liu, B.L.1
Robinson, M.2
Han, Z.Q.3
-
2
-
-
84933586864
-
Talimogene laherparepvec improves durable response ate in patients with advanced melanoma
-
Andtbacka, R.H., Kaufman, H.L., Collichio, F. et al. Talimogene laherparepvec improves durable response ate in patients with advanced melanoma. J Clin Oncol 2015, 33(25): 2780-8.
-
(2015)
J Clin Oncol
, vol.33
, Issue.25
, pp. 2780-2788
-
-
Andtbacka, R.H.1
Kaufman, H.L.2
Collichio, F.3
-
3
-
-
77149141965
-
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
-
Kaufman, H.L., Kim, D.W., DeRaffele, G., Mitcham, J., Coffin, R.S., Kim-Schulze, S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010, 17(3): 718-30.
-
(2010)
Ann Surg Oncol
, vol.17
, Issue.3
, pp. 718-730
-
-
Kaufman, H.L.1
Kim, D.W.2
DeRaffele, G.3
Mitcham, J.4
Coffin, R.S.5
Kim-Schulze, S.6
-
4
-
-
33845336115
-
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colonystimulating factor
-
Hu, J.C., Coffin, R.S., Davis, C.J. et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colonystimulating factor. Clin Cancer Res 2006, 12(22): 6737-47.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.22
, pp. 6737-6747
-
-
Hu, J.C.1
Coffin, R.S.2
Davis, C.J.3
-
5
-
-
79958043675
-
-
National Cancer Institute
-
Howlader, N., Noone, A.M., Krapcho, M. et al. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute, http://seer.cancer.gov/csr/1975-2011/.
-
SEER Cancer Statistics Review, 1975-2011
-
-
Howlader, N.1
Noone, A.M.2
Krapcho, M.3
-
6
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman, P.B., Hauschild, A., Robert, C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26): 2507-16.
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
7
-
-
84868224906
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
-
Flaherty, K.T., Infante, J.R., Daud, A. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367(18): 1694-703.
-
(2012)
N Engl J Med
, vol.367
, Issue.18
, pp. 1694-1703
-
-
Flaherty, K.T.1
Infante, J.R.2
Daud, A.3
-
8
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
Sosman, J.A., Kim, K.B., Schuchter, L. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366(8): 707-14.
-
(2012)
N Engl J Med
, vol.366
, Issue.8
, pp. 707-714
-
-
Sosman, J.A.1
Kim, K.B.2
Schuchter, L.3
-
9
-
-
84862908526
-
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors
-
Oberholzer, P.A., Kee, D., Dziunycz, P. et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012, 30(3): 316-21.
-
(2012)
J Clin Oncol
, vol.30
, Issue.3
, pp. 316-321
-
-
Oberholzer, P.A.1
Kee, D.2
Dziunycz, P.3
-
10
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8): 711-23.
-
(2010)
N Engl J Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
11
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert, C., Thomas, L., Bondarenko, I. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26): 2517-26.
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
-
12
-
-
3242677686
-
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
-
Latchman, Y.E., Liang, S.C., Wu, Y. et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 2004, 101(29): 10691-6.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, Issue.29
, pp. 10691-10696
-
-
Latchman, Y.E.1
Liang, S.C.2
Wu, Y.3
-
13
-
-
84929481481
-
Pembrolizumab versus ipilimumab in advanced melanoma
-
Robert, C., Schachter, J., Long, G.V. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015, 372(26): 2521-32.
-
(2015)
N Engl J Med
, vol.372
, Issue.26
, pp. 2521-2532
-
-
Robert, C.1
Schachter, J.2
Long, G.V.3
-
14
-
-
84879759020
-
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
-
Hamid, O., Robert, C., Daud, A. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369(2): 134-44.
-
(2013)
N Engl J Med
, vol.369
, Issue.2
, pp. 134-144
-
-
Hamid, O.1
Robert, C.2
Daud, A.3
-
15
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Wolchok, J.D., Kluger, H., Callahan, M.K. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2): 122-33.
-
(2013)
N Engl J Med
, vol.369
, Issue.2
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
-
16
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer, J.R., Tykodi, S.S., Chow, L.Q. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26): 2455-65.
-
(2012)
N Engl J Med
, vol.366
, Issue.26
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
-
17
-
-
84932628341
-
PD-1 blockade in tumors with mismatch-repair deficiency
-
Le, D.T., Uram, J.N., Wang, H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015, 372(26): 2509-20.
-
(2015)
N Engl J Med
, vol.372
, Issue.26
, pp. 2509-2520
-
-
Le, D.T.1
Uram, J.N.2
Wang, H.3
-
18
-
-
84927150740
-
Immune checkpoint blockade in cancer therapy
-
Postow, M.A., Callahan, M.K., Wolchok, J.D. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015, 33(17): 1974-82.
-
(2015)
J Clin Oncol
, vol.33
, Issue.17
, pp. 1974-1982
-
-
Postow, M.A.1
Callahan, M.K.2
Wolchok, J.D.3
-
19
-
-
0030807896
-
The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34
-
Brown, S.M., MacLean, A.R., McKie, E.A., Harland, J. The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34. J Virol 1997, 71(12): 9442-9.
-
(1997)
J Virol
, vol.71
, Issue.12
, pp. 9442-9449
-
-
Brown, S.M.1
MacLean, A.R.2
McKie, E.A.3
Harland, J.4
-
20
-
-
0042530129
-
The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins
-
Harland, J., Dunn, P., Cameron, E., Conner, J., Brown, S.M. The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins. J Neurovirol 2003, 9(4): 477-88.
-
(2003)
J Neurovirol
, vol.9
, Issue.4
, pp. 477-488
-
-
Harland, J.1
Dunn, P.2
Cameron, E.3
Conner, J.4
Brown, S.M.5
-
21
-
-
0030793170
-
Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: Failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene
-
He, B., Chou, J., Brandimarti, R., Mohr, I., Gluzman, Y., Roizman, B. Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997, 71(8): 6049-54.
-
(1997)
J Virol
, vol.71
, Issue.8
, pp. 6049-6054
-
-
He, B.1
Chou, J.2
Brandimarti, R.3
Mohr, I.4
Gluzman, Y.5
Roizman, B.6
-
22
-
-
0035902471
-
Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells
-
Taneja, S., MacGregor, J., Markus, S., Ha, S., Mohr, I. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci U S A 2001, 98(15): 8804-8.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, Issue.15
, pp. 8804-8808
-
-
Taneja, S.1
MacGregor, J.2
Markus, S.3
Ha, S.4
Mohr, I.5
-
23
-
-
0035036952
-
A herpes simplex virus type 1 gamma 34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals
-
Mohr, I., Sternberg, D., Ward, S., Leib, D., Mulvey, M., Gluzman, Y. A herpes simplex virus type 1 gamma 34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001, 75(11): 5189-96.
-
(2001)
J Virol
, vol.75
, Issue.11
, pp. 5189-5196
-
-
Mohr, I.1
Sternberg, D.2
Ward, S.3
Leib, D.4
Mulvey, M.5
Gluzman, Y.6
-
24
-
-
84863208397
-
Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope
-
Raafat, N., Sadowski-Cron, C., Mengus, C., Heberer, M., Spagnoli, G.C., Zajac, P. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope. Int J Cancer 2012, 131(5): E659-69.
-
(2012)
Int J Cancer
, vol.131
, Issue.5
, pp. E659-E669
-
-
Raafat, N.1
Sadowski-Cron, C.2
Mengus, C.3
Heberer, M.4
Spagnoli, G.C.5
Zajac, P.6
-
25
-
-
33845627785
-
Impact of protein kinase PKR in cell biology: From antiviral to antiproliferative action
-
Garcia, M.A., Gil, J., Ventoso, I., Guerra, S., Domingo, E., Rivas, C., Esteban, M. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 2006, 70(4): 1032-60.
-
(2006)
Microbiol Mol Biol Rev
, vol.70
, Issue.4
, pp. 1032-1060
-
-
Garcia, M.A.1
Gil, J.2
Ventoso, I.3
Guerra, S.4
Domingo, E.5
Rivas, C.6
Esteban, M.7
-
26
-
-
2342641580
-
Targets and mechanisms for the regulation of translation in malignant transformation
-
Clemens, M.J. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004, 23(18): 3180-8.
-
(2004)
Oncogene
, vol.23
, Issue.18
, pp. 3180-3188
-
-
Clemens, M.J.1
-
27
-
-
84875225339
-
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
-
Heo, J., Reid, T., Ruo, L. et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013, 19(3): 329-36.
-
(2013)
Nat Med
, vol.19
, Issue.3
, pp. 329-336
-
-
Heo, J.1
Reid, T.2
Ruo, L.3
-
28
-
-
84940824279
-
Oncolytic viruses: A new class of immunotherapy drugs
-
Kaufman, H.L., Kohlhapp, F.J., Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015, 14(9): 642-62.
-
(2015)
Nat Rev Drug Discov
, vol.14
, Issue.9
, pp. 642-662
-
-
Kaufman, H.L.1
Kohlhapp, F.J.2
Zloza, A.3
-
29
-
-
84863553090
-
Targeted and armed oncolytic poxviruses for cancer: The lead example of JX-594
-
Breitbach, C.J., Thorne, S.H., Bell, J.C., Kirn, D.H. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594. Curr Pharm Biotechnol 2012, 13(9): 1768-72.
-
(2012)
Curr Pharm Biotechnol
, vol.13
, Issue.9
, pp. 1768-1772
-
-
Breitbach, C.J.1
Thorne, S.H.2
Bell, J.C.3
Kirn, D.H.4
-
30
-
-
0034294865
-
Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colonystimulating factor
-
Toda, M., Martuza, R.L., Rabkin, S.D. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colonystimulating factor. Mol Ther 2000, 2(4): 324-9.
-
(2000)
Mol Ther
, vol.2
, Issue.4
, pp. 324-329
-
-
Toda, M.1
Martuza, R.L.2
Rabkin, S.D.3
-
31
-
-
73349133717
-
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma
-
Senzer, N.N., Kaufman, H.L., Amatruda, T. et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009, 27(34): 5763-71.
-
(2009)
J Clin Oncol
, vol.27
, Issue.34
, pp. 5763-5771
-
-
Senzer, N.N.1
Kaufman, H.L.2
Amatruda, T.3
-
32
-
-
84933586864
-
Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
-
Andtbacka, R.H., Kaufman, H.L., Collichio, F. et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol 2015, 33(25): 2780-8.
-
(2015)
J Clin Oncol
, vol.33
, Issue.25
, pp. 2780-2788
-
-
Andtbacka, R.H.1
Kaufman, H.L.2
Collichio, F.3
-
33
-
-
0033998594
-
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor
-
Spitler, L.E., Grossbard, M.L., Ernstoff, M.S., Silver, G., Jacobs, M., Hayes, F.A., Soong, S.J. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000, 18(8): 1614-21.
-
(2000)
J Clin Oncol
, vol.18
, Issue.8
, pp. 1614-1621
-
-
Spitler, L.E.1
Grossbard, M.L.2
Ernstoff, M.S.3
Silver, G.4
Jacobs, M.5
Hayes, F.A.6
Soong, S.J.7
-
34
-
-
84936821506
-
Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma
-
(May 29-June 2, Chicago) Abst 9063
-
Puzanov, I., Milhem, M.M., Andtbacka, R.H. et al. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. 51st Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Chicago) 2015, Abst 9063.
-
(2015)
51st Annu Meet Am Soc Clin Oncol (ASCO)
-
-
Puzanov, I.1
Milhem, M.M.2
Andtbacka, R.H.3
-
35
-
-
84944806473
-
Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade
-
(April 18-22, Philadelphia) Abst 258
-
Piasecki, J., Le, T., Ponce, R., Beers, C. Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade. 106th Annu Meet Am Assoc Cancer Res (AACR) (April 18-22, Philadelphia) 2015, Abst 258.
-
(2015)
106th Annu Meet Am Assoc Cancer Res (AACR)
-
-
Piasecki, J.1
Le, T.2
Ponce, R.3
Beers, C.4
-
36
-
-
84857815877
-
Immunologic correlates of the abscopal effect in a patient with melanoma
-
Postow, M.A., Callahan, M.K., Barker, C.A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366(10): 925-31.
-
(2012)
N Engl J Med
, vol.366
, Issue.10
, pp. 925-931
-
-
Postow, M.A.1
Callahan, M.K.2
Barker, C.A.3
-
37
-
-
84865782617
-
Optimizing cancer treatments to induce an acute immune response: Radiation abscopal effects, PAMPs, and DAMPs
-
Ludgate, C.M. Optimizing cancer treatments to induce an acute immune response: radiation Abscopal effects, PAMPs, and DAMPs. Clin Cancer Res 2012, 18(17): 4522-5.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.17
, pp. 4522-4525
-
-
Ludgate, C.M.1
-
38
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
-
Wolchok, J.D., Hoos, A., O'Day, S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15(23): 7412-20.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.23
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O'Day, S.3
-
39
-
-
84944741733
-
Cell substrates for the production of vaccines for human use
-
4th ed. Council of Europe: Strasbourg
-
European Directorate for the Quality of Medicines. Cell substrates for the production of vaccines for human use. In:Vol. European Pharmacopoeia 4th ed. Council of Europe: Strasbourg 2002
-
(2002)
European Pharmacopoeia
-
-
-
40
-
-
84855519656
-
Tests for extraneous agents in viral vaccines for human use
-
4th ed. Council of Europe: Strasbourg
-
European Directorate for the Quality of Medicines. Tests for extraneous agents in viral vaccines for human use. In:Vol. European Pharmacopoeia 4th ed. Council of Europe: Strasbourg 2002
-
(2002)
European Pharmacopoeia
-
-
|